Atturra (ATA) investor relations material

Executive summary

• FY 2026 revenue rose 17% year-over-year to AUD 351.8 million, driven mainly by acquisitions, with organic revenue flat due to reduced government spending; recurring and long-term client revenue made up 78% of total revenue, up from 58% in FY24.

• Underlying EBITDA was AUD 30.1 million, down 5% from the prior year, impacted by the termination of a key contract, but second-half EBITDA rose 27% year-over-year.

• Net profit after tax (NPAT) swung to a loss of AUD 21.7 million from a profit of AUD 9.1 million in FY25, primarily due to a AUD 22.8 million non-cash impairment of intangibles.

• Earnings per share dropped to AUD -0.0588 from 2.60 cents year-over-year, but adjusted EPSA was positive at AUD 0.0366.

• Operating cash flow improved from a AUD 13.4 million outflow in H1 to a AUD 22.5 million inflow in H2.

Financial highlights

• Gross margin was 33%, slightly down from 34% in the prior year, and remained stable despite revenue growth.

• Underlying NPATA fell to AUD 13.5 million from AUD 19.6 million year-over-year, a 31% decline.

• Cash balance at year-end was AUD 66 million, with net tangible assets at AUD 9.9 million; closing cash was down 28% from FY25.

• Borrowings increased to AUD 29.4 million, mainly due to the Blue Connections acquisition, up 57% year-over-year.

• Operating cash inflow for FY26 was AUD 9.1 million.

Outlook and guidance

• FY 2027 is expected to deliver record revenue, EBIT, and underlying EBITDA, with earnings heavily weighted to the second half and AI investments expected to generate returns from 2H FY27.

• Focus is on organic growth, operational efficiency, and an AI-first approach.

• Planned investments in AI (AUD 3 million) and Scholarion (over AUD 4 million) will impact H1 earnings, with benefits expected in H2 and beyond.

• Scholarion platform targeted to reach breakeven in FY28 and meaningful profit in FY29.

• Continued focus on EPS and cash conversion, with further share buybacks planned where value accretive.